| Login
| Connect 
Rosenblatt Sets Bullish Expectations on Oracle Corporation (ORCL) Ahead of F1Q18 Print
ORCL’s ability to show improving margins is key for short-term success, says analyst.
Here’s Why You Should Buy SAGE Therapeutics Inc (SAGE) Following Failure of SRSE Drug
J.P. Morgan believes key upcoming trials could boost investor sentiment.
Is New Teva Pharmaceutical Industries Ltd (ADR) (TEVA) CEO Walking into a Landmine? Oppenheimer and Maxim Weigh In
Here’s why analysts are playing it cautiously optimistic on the struggling pharmaceutical giant.
Rexahn Pharmaceuticals, Inc. (RNN) Phase 2a Update in Muscle Invasive Bladder Cancer Shows Promise, Cheers H.C. Wainwright
RNN’s Phase 2a results have analyst optimistic on RX-3117 drug for patients running out of options.
Cowen Positive on Sarepta Therapeutics Inc (SRPT) Following Successful Early-Stage DMD Trial
Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.
William Blair Sees Limited Downside Potential for Finisar Corporation (FNSR) in Light of Setback in 3-D Production
Strong datacom market drivers could spur revenue growth in second half of fiscal 2018, says analyst.
FuelCell Energy Inc (FCEL) Project Bookings Are Primary Catalysts for Growth: Roth Capital
Analyst sees $800 million in contract revenue potential for FuelCell.
Activision Blizzard, Inc. (ATVI) Destiny 2 Launch Could Provide Upside: Piper Jaffray
Top analyst takes note that Activision eyes Asian market with October PC release of newest video game.
Cowen Sees High 80% Probability of FDA Approval for Insmed Incorporated’s (INSM) NTM Drug
Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S., says top analyst.
Cowen Shares Key Insights on Gilead Sciences, Inc. (GILD) Following Management Meetings
Gilead is very confident on the successful commercial launch of Axi-Cel.